Weekly Digest - September 2024

Weekly Digest - September 2024

23 Sep 2024: Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

  • Innate Pharma has received FDA clearance for its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502
  • IPH4502 is a novel antibody-drug conjugate (ADC) that targets Nectin-4 and incorporates a topoisomerase I inhibitor
  • The study aims to evaluate the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric and colorectal cancers

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home